论文部分内容阅读
作者对50例已经证实为耐氨苯砜的麻风病人用利福平长期治疗(有的已达7年之久),对其临床和细菌学进行了研究。除1例病人为利福平600毫克每周一次外,余均为每天600毫克。大多数病人采用联合疗法(利福平加丁氨苯硫脲,后者每周注射一次1克或每日口服二次,每次1克),以期减少耐药的发生。各种检查结果的评价表明,所有病人不管其利福平治疗方案如何,均显示了良好和稳定的进步。初期临床进步特别快,与氨苯砜治疗2～3个月的疗效相比,利福平治疗的病人在2～3周内即已显效(尤其是鼻堵塞的消退)。从形态指数(MI)的下降来看,氨苯砜耐药病人和以往未经治疗过的瘤型病人二者在用利福平治疗后MI下降的速度一样快。然而细
The authors studied the clinical and bacteriological aspects of 50 patients with leprosy who have been identified as dapsone for the long-term treatment (some have been 7 years old). In addition to a patient with rifampicin 600 mg once a week, I was 600 mg per day. Most patients treated with combination therapy (rifampicin plus butaniline, the latter weekly injection of 1 g or twice daily oral, each 1 g), in order to reduce the incidence of drug resistance. Evaluation of the various test results showed that all patients showed good and steady progress regardless of their rifampicin regimen. The initial clinical progress is particularly rapid. Compared with the efficacy of dapsone for 2 to 3 months, the patients treated with rifampin have achieved good effect within 2 to 3 weeks (especially, the nasal congestion has subsided). From the decline of the morphological index (MI), MI decreased as rapidly after treatment with rifampin-resistant and untreated neoplasia patients after treatment with rifampicin. However fine